Official title: A Multicenter Open-label Phase 1 Trial to Evaluate Safety and Preliminary Efficacy of Endovascularly Applied Vascular Targeted Photodynamic Therapy (VTP) for Patients With Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma Summary: This is a prospective, multicenter, non-randomized, open label light dose escalation phase I trial to evaluate the safety and preliminary efficacy of Padeliporfin vascular targeted photodynamic therapy (VTP) applied via endovascular fiber placement within a dilatation catheter, through the target artery(superior mesenteric artery (SMA), celiac artery (CA) or common hepatic artery (CHA)). The investigators will evaluate safety and preliminary efficacy of Padeliporfin VTP administered endovascularly using light dose escalation. Conditions: Locally Advanced Unresectable Pancreatic Adenocarcinoma Study type: INTERVENTIONAL Primary purpose: TREATMENT Phases: PHASE1 Enrollment: 30 (ESTIMATED) Status: RECRUITING Completion: 2026-10-30 (ESTIMATED)
ClinicalTrials.gov published a clinical update in Oncology on 12 Feb 2026.
The item focuses on Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma.
Review the original article for the full source wording and details.